Actively Recruiting
mGlide-Care: A Partnership With Caregivers
Led by University of Minnesota · Updated on 2026-02-13
75
Participants Needed
1
Research Sites
123 weeks
Total Duration
On this page
Sponsors
U
University of Minnesota
Lead Sponsor
N
National Institute on Aging (NIA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Hypertension (HTN) is the most significant stroke, cardiovascular disease and dementia risk factor and is substantially under-treated especially in older persons. In this study the investigators will develop mGlide-Care to address uncontrolled HTN in people with mild cognitive impairment (MCI) and early stage Alzheimer's Disease and Alzheimer's Disease Related Dementia (AD/ADRD). mGlide-Care is adapted from mGlide which is a mHealth (mobile health technology) mediated care model for HTN care. Aim 1 will engage stakeholders to study the acceptability of mHealth mediated HTN care and will use their input to develop mGlide-Care. Stakeholders are persons with early stage AD/ADRD and MCI, unpaid family caregivers, primary care providers, geriatricians and clinical pharmacists. Aim 2 is a feasibility pilot to test mGlide-Care vs. usual care in 75 participants with uncontrolled HTN and early stage AD/ADRD or MCI. Caregivers will assist participants. Outcomes will include HTN control and participant and caregiver reported measures.
CONDITIONS
Official Title
mGlide-Care: A Partnership With Caregivers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with early stage Alzheimer's disease, Alzheimer's disease related dementia, or mild cognitive impairment
- Have uncontrolled hypertension
- Have an unpaid, family caregiver
- Have an established medical diagnosis of hypertension
- Speak English
- Participant or caregiver must have a smartphone or mobile device that can transmit blood pressure data
- Participant and caregiver must be able and willing to follow the entire study protocol
- Able to give voluntary written informed consent
You will not qualify if you...
- Severe comorbid illness such as end-stage kidney disease or liver disease, or life expectancy less than 1 year
- Medical complexity that prevents participation in the clinical trial
- Active use of illicit drugs like cocaine, methamphetamines, opioids, or phencyclidine
- Participant and caregiver unable to complete study tasks due to homelessness, planned relocation, or leaving the country within 12 months
- Serious psychiatric illness that impairs treatment or compliance, including schizophrenia or bipolar disorder
- Unable or unwilling to give consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Epidemiology Clinical Research Center
Minneapolis, Minnesota, United States, 55415
Actively Recruiting
Research Team
K
Kamakshi Lakshminarayan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here